Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 8th Floor 36 Dame Street, Dublin, Ireland

DoMoreCharity May. 12 at 9:56 PM

$AMRN https://www.globenewswire.com/news-release/2026/05/12/3293262/0/en/RECORDATI-STRONG-MOMENTUM-OF-THE-GROUP-CONTINUES-INTO-THE-FIRST-QUARTER-OF-2026-NET-REVENUE-4-9-EBITDA-1-5-0-ADJUSTED-NET-INCOME-2-7-2.html

0 · Reply

Patrick2343 May. 12 at 4:08 PM

$AMRN The denner master plan.

0 · Reply

ians May. 12 at 2:11 PM

$AMRN Could we get a decision as early as May 14th?!? 🤔🤞☘️💎 https://www.scotusblog.com/2026/05/announcement-of-opinions-for-thursday-may-14/

2 · Reply

CaptBeer May. 12 at 12:38 PM

$AMRN Does anyone here use Charles Schaub for their brokerage accounts? Have you noticed that they have placed trading restrictions on AMRN? You now have to place your trades through a live Broker.

6 · Reply

Rickstero May. 12 at 12:05 PM

$AMRN Did anyone notice that Short Shares increased by an additional $247,216 as of 04/30/2026?....More Manipulation!

1 · Reply

CEVIN May. 11 at 11:56 PM

$AMRN Is the shortage of Vascepa in any way connected with the Middle East Crude ”fish” oil blockade been over 10 weeks now …..

0 · Reply

CaptainScripts May. 11 at 11:44 PM

$AMRN Just picked up my 3 bottles of Vascepa. CVS was sold out a week ago and tried to give me generic. I laughed and said no thank you. I just opened up a bottle to take 2 g and it is the first time I remember that the pills say IPE vs Vascepa. Have I not paid attention to this. Is this new? Just asking if anyone else noticed this and if this has been going on for a long time.

3 · Reply

biffermeister May. 11 at 11:38 PM

$AMRN TGIM. what will be will be. https://www.youtube.com/watch?v=PSHo146tQjQ

1 · Reply

CEVIN May. 11 at 11:37 PM

$AMRN Doesn’t time fly has it really been over TWO YEARS since we last managed to stay above $1.00 (post reverse split) - All the same spin month after month but still no value added for shareholders.

0 · Reply

declanaidan May. 11 at 7:17 PM

$AMRN With the annual "meeting" in Dublin Wednesday, five hours ahead of US east coast, we should know results of voting early in trading day. Management already knows. But the vote will give us, and management, some inclination of where things go from here. In any event, it clears the deck for a path forward.

3 · Reply

Amarin Reports 2026 First Quarter Financial Results

Apr 15, 2026, 8:00 AM EDT - 4 weeks ago

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

2026-03-18T12:41:54.000Z - 2 months ago

Amarin highlights new recommendation for treatment of CV risk

2026-03-16T12:27:24.000Z - 2 months ago

Amarin to present data in patients at extreme cardiovascular risk

2026-03-02T13:26:30.000Z - 2 months ago

Amarin highlights recent data published on REDUCE-IT study

2026-02-25T12:14:50.000Z - 2 months ago

Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities

2026-02-23T13:23:34.000Z - 2 months ago

Amarin issues call to action for American Heart Month

Feb 23, 2026, 8:00 AM EST - 2 months ago

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Jan 16, 2026, 2:44 PM EST - 4 months ago

US Supreme Court to hear 'skinny label' patent fight involving Amarin

2026-01-09T12:13:43.000Z - 4 months ago

Amarin comments on recent innovations for patients with elevated triglycerides

Jan 9, 2026, 7:00 AM EST - 4 months ago

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

2026-01-08T12:06:26.000Z - 4 months ago

Amarin expects Q4 net revenue $48M-$43M

2025-11-10T00:10:10.000Z - 6 months ago

Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

Nov 9, 2025, 4:15 PM EST - 6 months ago

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 3, 2025, 8:30 AM EST - 6 months ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

2025-10-29T11:11:18.000Z - 7 months ago

Amarin reports Q3 EPS (2c) vs (6c) last year

2025-10-27T12:05:31.000Z - 7 months ago

Amarin issues statement related to recent action by FDA for fenofibrate drugs

2025-10-14T12:10:55.000Z - 7 months ago

Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

2025-09-01T12:30:11.000Z - 9 months ago

Amarin presents new REDUCE-IT analyses

Aug 31, 2025, 8:30 AM EDT - 9 months ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 9 months ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

2025-08-25T12:05:06.000Z - 9 months ago

Amarin announces upcoming presentations at ESC Congress 2025

Aug 25, 2025, 8:00 AM EDT - 9 months ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

2025-07-30T11:11:52.000Z - 10 months ago

Amarin expects accelerated in-market demand in Europe

Jul 30, 2025, 7:00 AM EDT - 10 months ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 10 months ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

2025-06-24T11:05:33.000Z - 11 months ago

Amarin announces exclusive license, supply agreement with Recordati

Jun 24, 2025, 7:05 AM EDT - 11 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

2025-04-29T20:40:18.000Z - 1 year ago

Amarin regains compliance with Nasdaq

Apr 29, 2025, 4:15 PM EDT - 1 year ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 1 year ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 1 year ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 1 year ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 1 year ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 27, 2025, 9:00 AM EST - 1 year ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 2 years ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 2 years ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 2 years ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 2 years ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 2 years ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 2 years ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 2 years ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 7:00 AM EST - 2 years ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 8:00 AM EST - 2 years ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Jan 22, 2024, 7:30 AM EST - 2 years ago

Amarin Chairman & CEO Issue Letter to Shareholders

Jan 10, 2024, 7:00 AM EST - 2 years ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Dec 11, 2023, 8:00 AM EST - 2 years ago

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 4, 2023, 4:23 PM EST - 2 years ago

Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership

Nov 12, 2023, 9:00 AM EST - 2 years ago

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Amarin Reports Third Quarter 2023 Financial Results

DoMoreCharity May. 12 at 9:56 PM

0 · Reply

Patrick2343 May. 12 at 4:08 PM

$AMRN The denner master plan.

0 · Reply

ians May. 12 at 2:11 PM

$AMRN Could we get a decision as early as May 14th?!? 🤔🤞☘️💎 https://www.scotusblog.com/2026/05/announcement-of-opinions-for-thursday-may-14/

2 · Reply

CaptBeer May. 12 at 12:38 PM

$AMRN Does anyone here use Charles Schaub for their brokerage accounts? Have you noticed that they have placed trading restrictions on AMRN? You now have to place your trades through a live Broker.

6 · Reply

Rickstero May. 12 at 12:05 PM

$AMRN Did anyone notice that Short Shares increased by an additional $247,216 as of 04/30/2026?....More Manipulation!

1 · Reply

CEVIN May. 11 at 11:56 PM

$AMRN Is the shortage of Vascepa in any way connected with the Middle East Crude ”fish” oil blockade been over 10 weeks now …..

0 · Reply

CaptainScripts May. 11 at 11:44 PM

3 · Reply

biffermeister May. 11 at 11:38 PM

$AMRN TGIM. what will be will be. https://www.youtube.com/watch?v=PSHo146tQjQ

1 · Reply

CEVIN May. 11 at 11:37 PM

0 · Reply

declanaidan May. 11 at 7:17 PM

3 · Reply

NilsSB May. 11 at 4:22 PM

$AMRN

0 · Reply

RallyReaper May. 11 at 2:31 PM

$AMRN

0 · Reply

buygreensellredchop May. 10 at 9:35 PM

$AMRN Anyone know whats sort of damages Amrn could score from Hikma? Whats a realistic payout?

2 · Reply

CaptBeer May. 10 at 7:18 PM

$AMRN https://www.linkedin.com/posts/michael-everts-34799334_ipe-share-7459320879274102784-aRqS?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAdDmycBzT_CwLIulyFqANe8SLMF4KH2Odo

0 · Reply

SanDiegoLiving May. 10 at 6:15 PM

$AMRN 🩸VENOUS THROMBOSIS PATENT LANE GETS BUYER-READY ⚖️ Amarin has more than one patent lane currently moving through the USPTO. Alongside the LR-EtEPA file, App. 18/557,119 is active around EPA-based methods originally framed as "endothelial dysfunction". Live USPTO Patent Center sequence: 📍 6/27/25 — POA filed 📍 7/7/25 — POA change recorded 📍 1/7/26 — Restriction / election mailed 📍 3/26/26 — IDS filed 📍 5/6/26 — Election response filed 📍 5/9/26 — Forwarded to examiner The claim pivot: 🔍 Broad endothelial language narrowed → treating / preventing venous thrombosis. That points toward a DVT/VTE lane. Why would an acquirer care? Because VTE is not a tiny clinical bucket. U.S. alone: 🩸 up to 900k affected/year ⚰️ 60k–100k deaths/year 🏥 major hospital-associated risk 🧬 cancer-associated thrombosis angle 💰 multibillion-dollar annual burden ⌛ If usable claims issue, the patent turns into a disease-specific EPA optionality in a serious thrombosis market.

3 · Reply

DoMoreCharity May. 10 at 1:41 PM

$AMRN https://www.linkedin.com/posts/jonathan-provoost-5b02343_patientfirst-healthcareinnovation-iplaw-activity-7457881335035047936-8jNB?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAappXEBEo5xWglK2bmEx478x0aaRWW4o7I

0 · Reply

EnVila May. 10 at 8:44 AM

$AMRN New trial announced: "Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia (TIN-CAP)", by University of Ottawa Heart Institute. The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is: What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP. https://clinicaltrials.gov/study/NCT06710080

3 · Reply

DoMoreCharity May. 9 at 1:26 AM

$AMRN ELIGIBILITY FOR ICOSAPENT ETHYL IN PATIENTS UNDERGOING CARDIAC REHABILITATION: A REAL–WORLD COHORT STUDY European Heart Journal Supplements, Volume 28, Issue Supplement_6, May 2026, Published: 07 May 2026 https://academic.oup.com/eurheartjsupp/article/28/Supplement_6/suag058.542/8671000

1 · Reply

ians May. 8 at 7:54 PM

$AMRN $93 Fair Value 👏 SCOTUS, let justice prevail. ⚖️🇺🇸 And the Lord will grant us $120-150 BO. 🙏☘️💎

2 · Reply

Downtownguy May. 8 at 1:06 AM

$AMRN Walgreens out of stock for a week…

4 · Reply

SanDiegoLiving May. 8 at 12:04 AM

$AMRN 🧬 DDW 2026: PREPARE’S EPA FOOTPRINT IN COLORECTAL BIOLOGY 🔥 Presented May 2, 2026. Mass General / Harvard PREPARE is getting harder to ignore. 2024 posted results showed 4g/day icosapent ethyl reached colorectal tissue: ➡️ 0.54% before ➡️ 2.95% after 💡 Roughly a 5x increase. Now DDW adds the next layer: 🌟 IPE significantly shifted the fecal metabolome. Plain English: 🧪 EPA reached tissue, then CHANGED gut chemistry. Colorectal cancer biology is tied to: 🔥 inflammation 🛡️ immune signaling 🧬 host–microbiome interaction 🎯 gut lining biology 🧪 lipid mediator balance Nuance: ❌ Microbiome population did not massively change. Cleaner read: ✔️ EPA changed the gut chemical/lipid environment. PREPARE = mechanism. EMT2 tests whether that biology translates into recurrence/progression benefit after colorectal cancer liver-metastasis surgery. ⌛ Interesting timing: next from PREPARE is tissue RNA sequencing, as EMT2 sets to read out publicly in <90 days.

2 · Reply

DogDaze1 May. 7 at 11:41 PM

$AMRN Only down 116.20 a share.

1 · Reply

Market Cap	312.48M
Revenue (ttm)	213.65M
Net Income (ttm)	-38.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.16%
Debt to Equity Ratio	0.00

Volume	27,600
Avg Vol	68,814
Day's Range	N/A - N/A
Shares Out	20.80M
Stochastic %K	76%
Beta	0.81
Analysts	Hold
Price Target	$12.00